Where is Lemna located?

Lemna is headquartered in Switzerland.

How many employees does Lemna have?

As of Sep 30, 2026, the latest employee count at Lemna is 7.

Is Lemna a funded company?

Lemna is a funded company, having raised a total of $188K across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 15, 2025.

When was the latest funding round of Lemna?

Lemna's latest funding was a $***** Conventional Debt round on Dec 17, 2025, with participation from 1 investor. Its primary sector is Artificial Intelligence. In Switzerland, the Artificial Intelligence sector has seen $298M in funding in 2026 to date.

Where does Lemna rank among its competitors?

Lemna ranks 714th amongst 2031 active competitors, of which 449 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was One Biosciences, which secured $3.76M in Sep, 2026.

Who are the top competitors of Lemna?

Lemna's top competitors include Antheia, Synthego and Axol Bioscience. Among them, One Biosciences secured the most recent funding round in September, 2026.

Lemna - 2026 Company Profile, Funding & Competitors

Lemna is a seed company based in Switzerland. It operates as a Lemna Bio | An atomic-resolution AI framework for biological reasoning.. Lemna has raised $188K in funding. The company has 2031 active competitors, including 449 funded and 321 that have exited. Its top competitors include companies like Antheia, Synthego and Axol Bioscience.

Company Details

Biological interactions are at the core of health and disease. We build AI models that explain how molecules interact across scales, from atomic interfaces to biological networks. Our mission is to make early-stage drug discovery outcomes mechanistically predictable.

Key Metrics

Location

Switzerland

Stage

Seed

Total Funding

$188K in 2 rounds

Latest Funding Round

Conventional Debt, Dec 17, 2025, $*****

Investors

Venture Kick & 1 more

Ranked

714^th among 2031 active competitors

Employee Count

7 as on Sep 30, 2026

Similar Companies

OpenEvidence & 5601 more

View Lemna's full profile

Lemna has raised a total funding of $188K over 2 rounds. Its first funding round was on Sep 15, 2025. Its latest funding round was a Conventional Debt round on Dec 17, 2025 for $*****. 1 investor participated in its latest round. Lemna has 2 institutional investors.

Here is the list of recent funding rounds of Lemna:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 17, 2025	6573412	Conventional Debt	2183784	9203472	6671133	1511337
Sep 15, 2025	2679077	Seed	5048746	5692983	6482526	Venture Kick

Access funding benchmarks and valuations. Sign up today!

View details of Lemna's funding rounds and investors

Lemna's employee count trend

Lemna has 7 employees as of Sep 26. Here is Lemna's employee count trend over the years:

Uncover Lemna's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lemna include Antheia, Synthego and Axol Bioscience. Here is the list of Top 10 competitors of Lemna, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	68/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Manufacturer of custom CRISPR gene editors and molecular biology reagents	$460M	8VC, Perceptive Advisors & 30 others	67/100
3rd	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	65/100
4th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 15 others	65/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, Norwest & 22 others	64/100
8th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Hercules Capital, Lumira Ventures & 15 others	63/100
9th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Decheng Capital, Eclipse	63/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 7 others	63/100
714th	Lemna Switzerland, Seed	Lemna Bio \| An atomic-resolution AI framework for biological reasoning.	$188K	Venture Kick, FIT	30/100